Table 2.

Types of cancer therapy and their associated cardiotoxicity risk

Cancer therapy	LVD	Myocarditis	HTN	Valve disease	Coronary spasm	Coronary thrombosis	Atherosclerosis	Pericardial constriction	Pericardial effusions	Pulmonary HTN	QT -prolongation	Arrhythmia	Conduction disease
Anthracyclines	+++								+			+
HER2 Monoclonal Antibodies	+++
VEGF monoclonal antibodies	++		+++			++
BCR-ABL tyrosine kinase inhibitors	++*	++*		++*			++*	++*	++*
VEGF tyrosine kinase inhibitors	++		+++			++					+++
Bruton kinase inhibitor			++									++
Immune checkpoint inhibitors	++	++
Proteasome inhibitors	++	++	+++			++				++
Fluoropyrimidines					+++	++						+
Arsenic trioxide									+++		+++
Alkylating agents	++					++			+	+
All-transretinoic acid									++
Immunomodulatory drugs (myeloma)	++					++						++
Radiotherapy (mantle/high dose)	++		+++	+++			+++	++					++
Radiotherapy (low dose)			++	++			++

The risk assigned to each treatment represents an overview of the overall risk associated with that class of chemotherapy treatment; however, drug-specific risk within each category may lie outside the range listed. +++, treatment associated with > 10% risk of developing that form of cardiotoxicity; ++ risk is estimated to be between 1% and 10%; +, risk estimated to be < 1%; *, drug-dependent risk; LVD (left ventricular dysfunction); HTN (hypertension); CAD (coronary artery disease)